Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade

NCT06630481 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT06630481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06630481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
Lead sponsor
Seoul National University Hospital
Phase
Observational
Overall status
Completed
Start date
January 1, 2009
Completion date
September 1, 2024
Enrollment
462 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant therapy, pancreatic cancer, pathological complete response